CELLULAR HEALTH

Do Oral NAD+ Precursors Improve Human Healthspan or Only Blood NAD+?

Human trials of nicotinamide riboside and nicotinamide mononucleotide reliably elevate circulating NAD+ metabolites, but functional changes in muscle, insulin sensitivity, and vascular stiffness remain inconsistent.

LetsGo Editorial · LetsGo Editorial · 5 November 2026 · 12 min read

A higher blood NAD+ number on a laboratory report is not a clinical healthspan outcome, and a commercial intravenous NAD+ drip is not the intervention tested in published precursor trials.

Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide present in all living cells. It functions both as a redox cofactor in mitochondrial energy production and as a consumed substrate for enzymes that regulate DNA repair, epigenetic maintenance, and cellular stress responses. Because tissue NAD+ concentrations decline in several rodent models of aging and in specific human tissues such as skin, skeletal muscle, and brain, restoring NAD+ pools has become a central target in cellular resilience research. However, a sharp divide exists between rodent pharmacology and human clinical data. Through 2025, human randomized controlled trials (RCTs) of the oral precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) consistently demonstrate elevated NAD+ and its breakdown products in whole blood and peripheral blood mononuclear cells (PBMCs). Yet those same trials largely report null or modest, tissue-specific results for clinical endpoints like insulin sensitivity, endothelial function, and physical performance. Furthermore, intravenous (IV) intact NAD+ infusions offered in commercial clinics represent a completely separate biochemical and pharmacokinetic intervention from oral precursor supplementation.

What it is

NAD+ and its reduced form, NADH, transfer electrons during glycolysis, fatty acid beta-oxidation, and the tricarboxylic acid (TCA) cycle to drive mitochondrial oxidative phosphorylation and ATP synthesis. Beyond redox reactions, NAD+ is consumed as a co-substrate by three major classes of enzymes: sirtuins (SIRT1 through SIRT7, which deacetylate histones and metabolic regulators like PGC-1alpha), poly(ADP-ribose) polymerases (PARP1 and PARP2, which detect and repair single- and double-strand DNA breaks), and cyclic ADP-ribose synthases (predominantly CD38 and CD157, ectoenzymes on immune and endothelial cells that regulate calcium signaling). Mammalian cells cannot import intact NAD+ across the plasma membrane efficiently because the molecule is large, phosphorylated, and polar. Instead, tissues maintain NAD+ pools through three synthesis pathways: the de novo pathway from dietary tryptophan, the Preiss-Handler pathway from nicotinic acid (niacin), and the salvage pathway, which recycles nicotinamide (NAM) back into NMN via the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT), and then into NAD+ via nicotinamide mononucleotide adenylyltransferases (NMNAT1–3). Oral supplements target the salvage pathway using two main precursors: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NR is a nucleoside transported directly into cells via equilibrative nucleoside transporters (ENTs) and phosphorylated into NMN by nicotinamide riboside kinases (NRK1 and NRK2). NMN is a nucleotide; in humans and rodents, a large fraction of oral NMN is dephosphorylated to NR at the gut lumen or cell surface by CD73 before crossing the cell membrane, though a putative solute carrier (SLC12A8) has been proposed in murine small intestine.

Furthermore, isotope-tracing studies in mice demonstrate that a substantial portion of orally administered NR and NMN does not reach systemic circulation intact. Instead, gut microbiota deamidate these precursors into nicotinic acid, which enters the liver via the portal vein to boost hepatic NAD+ via the Preiss-Handler pathway, releasing nicotinamide into general circulation. Commercial intravenous (IV) NAD+ drips bypass the gut by infusing intact NAD+ directly into a peripheral vein. Because intact NAD+ still cannot cross plasma membranes directly in most tissues, infused NAD+ is rapidly hydrolyzed in the extracellular space by ectoenzymes (CD38, CD73, and nucleotide pyrophosphatases) into NMN, NR, nicotinamide, and adenosine. The acute spike in extracellular adenosine and purinergic signaling explains why rapid IV NAD+ infusions cause immediate chest pressure, abdominal cramping, nausea, and bradycardia or tachycardia—effects absent with oral NR or NMN.

Why it is used

Cross-sectional human studies using phosphorus-31 magnetic resonance spectroscopy (31P-MRS) and tissue biopsies show that cellular NAD+ concentrations decline by roughly 10% to 50% between young adulthood and advanced age in skeletal muscle, brain, liver, and skin, though individual variance is wide. Two mechanisms drive this age-related decline: reduced synthesis via lower NAMPT expression, and accelerated consumption. Chronic low-grade inflammation and senescent cell accumulation secrete pro-inflammatory cytokines (TNF-alpha, IL-6) that upregulate CD38 expression on macrophages and endothelial cells. In preclinical mouse models and human tissue explants, CD38 acts as the primary sink for cellular NAD+, degrading both NAD+ and extracellular NMN. Simultaneously, cumulative oxidative nuclear DNA damage chronically activates PARP1, which consumes large quantities of NAD+ to build poly(ADP-ribose) chains, starving sirtuins of the substrate required for mitochondrial biogenesis and chromatin silencing. Preclinical studies in rodents show that restoring NAD+ with NR or NMN reverses age-related vascular endothelial dysfunction, improves glucose tolerance, protects against noise-induced hearing loss, and restores skeletal muscle capillary density. Consequently, clinical research investigates NAD+ modulation to support mitochondrial recovery, maintain insulin sensitivity, preserve vascular elasticity, and buffer against cellular stress during aging.

How it helps

More than 30 published human RCTs through 2025—typically enrolling 20 to 130 healthy middle-aged, older, or overweight adults for 4 to 24 weeks—demonstrate that oral NR and NMN consistently raise whole-blood or PBMC NAD+ by 40% to 150%, alongside 5- to 20-fold increases in turnover metabolites like NAAD and methylated nicotinamide (MeNAM). However, clinical outcomes across tissues remain mixed, and no reliable effect size exists for general healthspan extension in healthy humans. Why blood NAD+ rises while muscle outcomes stay flat: Whole-blood NAD+ assays measure circulating erythrocytes and leukocytes, cells directly exposed to portal and systemic precursor fluxes. Skeletal muscle, by contrast, tightly regulates its internal NAD+ pool via homeostatic feedback and has high starting point salvage capacity. In human RCTs performing vastus lateralis muscle biopsies after 3 to 12 weeks of NR or NMN supplementation, absolute intramuscular NAD+ concentration rarely changes compared to placebo. Instead, muscle biopsies show elevated levels of NAAD and methylated clearance metabolites (MeNAM, Me2PY, Me4PY). This indicates that excess precursor entering resting human muscle is rapidly metabolized and excreted rather than stored as a larger functional NAD+ pool, unless there is a true starting point deficiency or an active metabolic demand such as exercise training. Metabolic and insulin sensitivity: Most human RCTs in obese, insulin-resistant men and women using hyperinsulinemic-euglycemic clamps (the gold standard for insulin sensitivity) show zero effect of oral NR on peripheral glucose disposal, hepatic glucose production, or HbA1c over 6 to 12 weeks. A notable exception is a 10-week RCT of oral NMN in 25 postmenopausal women with prediabetes, which demonstrated an approximate 25% improvement in skeletal muscle insulin sensitivity (glucose disposal rate) and enhanced insulin-stimulated phosphorylation of AKT and mTOR, without changing liver fat, visceral adiposity, or fasting blood glucose.

Vascular and physical function: In a crossover RCT of 24 healthy middle-aged and older adults, 6 weeks of oral NR lowered systolic blood pressure by roughly 4 mmHg and reduced carotid-femoral pulse wave velocity (a measure of aortic stiffness) in the subgroup with elevated starting point blood pressure, though larger confirmatory trials have not established a consistent effect size. For physical performance, a few 6- to 12-week NMN trials in older adults and amateur runners report modest improvements in 6-minute walk distance, gait speed, or ventilatory threshold, while multiple parallel RCTs report no change in grip strength, leg extension peak torque, or VO2max. Neurological target engagement: Small Phase I/II trials in Parkinson's disease and ataxia (20 to 30 patients over 4 to 12 weeks) using 31P-MRS or cerebrospinal fluid (CSF) sampling show that oral NR increases brain NAD+ by roughly 10% to 15% and alters cerebral metabolic network patterns, establishing human central nervous system target engagement, though long-term disease modification remains unproven.

Who should try it

Twelve weeks of aerobic and resistance exercise training increases skeletal muscle NAMPT protein content by 15% to 30% in older adults according to human biopsy studies, reversing age-related declines in intramuscular NAD+ salvage without exogenous precursors. Oral NR or NMN is a secondary option for adults aged 45 and older who already maintain structured aerobic and resistance training, adequate sleep, and glycemic control, and who wish to test whether elevating systemic NAD+ availability improves specific tracked biomarkers. They are also studied in older adults with documented prediabetes or age-related declines in submaximal walking endurance. Trade-offs, side effects, and contraindications: Oral NR and NMN are well tolerated in RCTs lasting up to 24 weeks, with mild gastrointestinal upset, nausea, or flushing occurring at rates similar to placebo. However, two biological trade-offs require attention: 1. Methyl group depletion and vascular metabolites: Excess nicotinamide generated from NAD+ breakdown is cleared by the enzyme nicotinamide N-methyltransferase (NNMT), which consumes S-adenosylmethionine (SAMe), the body's primary methyl donor, producing methylated metabolites (MeNAM, 2PY, 4PY) excreted in urine. Furthermore, human genetic and observational cohort data published in 2024 linked elevated circulating levels of the terminal niacin/NAD+ metabolites 2PY and 4PY with increased vascular cell adhesion molecule-1 (VCAM-1) expression and higher risk of major adverse cardiovascular events. Whether chronic oral NR or NMN supplementation drives clinically harmful levels of 2PY/4PY in healthy adults remains an unresolved safety question. 2. Oncology and senescence: Because PARP1 and sirtuins support DNA repair and glycolysis in rapidly dividing cells, preclinical mouse models show that boosting NAD+ can accelerate the growth of existing tumors (such as glioblastoma and pancreatic ductal adenocarcinoma) and increase the senescence-associated secretory phenotype (SASP) of senescent cells. Consequently, individuals with active malignancy, uninvestigated suspicious lesions, or a strong personal history of hormone- or metabolism-sensitive cancers should avoid NAD+ precursors outside of clinical trials. Opportunity cost: Oral precursors cost roughly $50 to $150 per month; commercial IV NAD+ infusions cost $300 to $1,000+ per session, require 2 to 4 hours per infusion due to rate-limiting autonomic side effects, and lack published RCT data demonstrating superiority over oral precursors for any human healthspan endpoint.

Measurements that show improvement

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays of dried blood spots or isolated PBMCs directly quantify intracellular NAD+ target engagement before and 8 to 12 weeks after starting an intervention. An effective oral precursor regimen raises whole-blood NAD+ by 40% to 150% from starting point, confirming intestinal absorption and systemic salvage rather than tissue rejuvenation. Metabolic and vascular markers: Track fasting insulin and fasting glucose to calculate HOMA-IR (a downward trend toward <1.0 indicates improved hepatic insulin sensitivity), HbA1c, and resting seated blood pressure (a reduction of 3 to 5 mmHg in systolic blood pressure is clinically meaningful when starting point systolic pressure exceeds 120 mmHg).

Methylation and hepatic safety: Measure plasma homocysteine (an increase above 10–12 µmol/L signals SAMe and methyl donor strain from clearing excess nicotinamide) and a standard hepatic panel (AST, ALT, alkaline phosphatase) to rule out hepatotoxicity, which is classically associated with high-dose nicotinic acid or nicotinamide rather than NR or NMN, but remains prudent to monitor. Inflammatory and autonomic functional metrics: Track high-sensitivity C-reactive protein (hs-CRP, targeting <1.0 mg/L), overnight heart rate variability (HRV, looking for a sustained upward trend in RMSSD over 4+ weeks), resting heart rate, VO2max (via cardiopulmonary exercise testing), and grip strength via handheld dynamometry. Within a physician-led framework such as a LetsGo program, combining blood biomarker panels with composite biological age tracking helps separate interventions that merely shift a single metabolite from those that improve integrated physiological resilience.

Products and services

These LetsGo products and services sit next to this subject. They are not a prescription. A link is not evidence that the product causes the change discussed above. - [Grokki longevity programme](/programs/grokki/longevity) — A coached plan that can track the markers named in this article. - [LetsGo supplement shelf](/supplements) — Bottles LetsGo stocks for members. Read the label before the first order. A link is not a dose.

Practical takeaways

- Complete at least 12 weeks of structured progressive resistance and aerobic training (3 to 4 sessions per week) to upregulate skeletal muscle NAMPT by 15% to 30% before trialing exogenous NAD+ precursors.
- Use LC-MS/MS whole-blood NAD+ testing at starting point and week 8 (expecting a 40% to 150% increase) strictly to confirm supplement absorption and compliance, not as a proxy for muscle mitochondrial function.
- Measure starting point and 12-week fasting insulin, fasting glucose (targeting HOMA-IR <1.0), HbA1c, hs-CRP (<1.0 mg/L), and seated systolic blood pressure; discontinue the precursor at 12 weeks if no objective marker improves.
- Check plasma homocysteine and liver transaminases (AST, ALT) at starting point and week 12; stop supplementation or address methylation support with a physician if homocysteine rises above 10 to 12 µmol/L or transaminases exceed the upper limit of normal.
- Avoid commercial IV NAD+ infusions and discontinue all oral NAD+ precursors immediately if diagnosed with an active malignancy or investigating a suspicious lesion.

Safety note

NAD+ precursors are contraindicated in individuals with active malignancies due to preclinical evidence that elevated NAD+ supports tumor metabolism and PARP-mediated DNA repair in rapidly dividing cells. Pregnant or lactating women should avoid NR and NMN due to a lack of human reproductive safety data. Monitor plasma homocysteine and liver enzymes (AST, ALT) during prolonged use.

Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified physician or healthcare provider before starting any new supplement, intravenous therapy, or physiological monitoring guide.

Human clinical trials through 2025 confirm that oral NR and NMN are bioavailable precursors that reliably elevate NAD+ and its turnover metabolites in blood by 40% to 150%, and in brain tissue by 10% to 15%. However, elevating blood NAD+ does not enlarge resting skeletal muscle NAD+ pools or consistently improve insulin sensitivity, VO2max, or physical function over 4 to 24 weeks. Commercial IV NAD+ infusions remain an

unvalidated, side-effect-prone delivery method distinct from oral precursor pharmacology. For adults aged 40 to 65, structured aerobic and resistance exercise remains the only intervention proven in human biopsies to restore endogenous muscle NAMPT and NAD+ salvage while simultaneously improving VO2max, HOMA-IR, and vascular compliance.